Effekt von p-Bromophenacylbromid, einem Phospholipase A-Hemmer, bei experimenteller akuter Pankreatitis der Ratte

Translated title of the contribution: The effect of p-bromophenacylbromide, an phospholipase A-inhibitor, in experimental acute pancreatitis in rats

G. Zöch, E. Roth, N. Hölbling, J. Karner, J. Funovics, K. Czerwenka

Research output: Contribution to journalArticle

2 Citations (Scopus)


In this study the effect of p-bromophenacylbromide (p-BPAB), an inhibitor of phospholipase A, was studied in acute pancreatitis in an experimental rat model. Acute pancreatitis was produced by instillation of 0.4 ml bile into the pancreatic duct. p-BPAB was injected i.p. in a dosage of 0.25 μg/g b.wt. 30 min before, 30 min after, or 4 h after the onset of pancreatitis. Prophylactic and early administration of p-BPAB inhibited severe morphological changes, such as necrosis and hemorrhages. Moreover, during administration of the inhibitor, decreased plasma concentrations of serum lipase and amylase (P<0.001) were monitored and compared with untreated animals. These therapeutic effects of p-BPAB were not seen in rats in which the inhibitor was injected 4 h after the onset of pancreatitis. As a result the phospholipase inhibitor, p-BPAB, reduces the clinical and morphological manifestations of acute pancreatitis. The effect of p-BPAB is dependent on the time of administration.

Original languageGerman
Pages (from-to)179-189
Number of pages11
JournalResearch In Experimental Medicine
Issue number3
Publication statusPublished - Jul 1 1984



  • Experimental acute pancreatitis
  • Phospholipase A
  • Phospholipase A inhibitor
  • p-Bromophenacylbromide

ASJC Scopus subject areas

  • Medicine(all)

Cite this